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Abstract 
 
Regulatory Science Ireland (RSI) is a voluntary network of interested parties from academia, the Health 
Products Regulatory Authority (HPRA), pharmaceutical and medical device industries and government 
agencies.  RSI is conducting a research project, the objective of which is to enhance understanding of 
biosimilar medicines amongst stakeholders and encourage best practice in the use of these medicines.   
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Regulatory Science Ireland  
 
The ever increasing complexity of health care products requires a data driven, evidence based 
approach to their regulation.  The European Medicine Agency (EMA) has identified regulatory science 
as a key driver to meet its mission of fostering ‘scientific excellence in the evaluation and supervision 
of medicines’ (1).  Regulatory science is becoming increasingly important as an approach to how 
medicines are developed and regulated.  The EMA recognises this fact and recommends that 
regulators work closely with academia, industry, expert patient groups and others in order to support 
developments in this area (2).   
 
RSI is an integrated Irish response to global regulatory science initiatives.  The group is composed of 
interested parties from the HPRA, academia, pharmaceutical industry, medical devices industry and 
government agencies (see Figure 1).  RSI is contributing to the regulatory science effort by conducting 
research, provision of educational materials and organisation of regulatory symposia. Efforts such as 
these will help improve regulatory understanding among all stakeholders and will ultimately be of real 
benefit to patients.  
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Figure 1: Regulatory Science Ireland Membership 
  
 
Why is RSI focusing on biological and biosimilar medicines?  
 
A biological medicine is a medicine that contains an active substance made by a biological process or 
derived from a biological source.  The standards for the quality, safety and efficacy of biological 
medicines are complex and it is essential that healthcare professionals involved in their clinical use 
and supply are appropriately informed of their unique characteristics.  Biosimilar medicines are 
biological medicines which contain a version of the active substance of an already authorised 
biological medicine (reference medicine).  Manufacturers of biosimilar medicines must perform an 
extensive head-to-head comparability exercise with the reference medicine and demonstrate to 
regulators that the biosimilar medicine has similar quality, safety and efficacy to the reference 
medicine such that there are no clinically meaningful differences between the two.   
 
The biosimilar approval process is based predominantly on evidence generated from the quality and 
pre-clinical comparability exercise. The extent of clinical data needed to demonstrate similarity in 
addition to the quality and non-clinical data is tailored to each product on a case by case basis and is 
considered confirmatory in nature.  Therefore depending on the nature of the product, the clinical 
data can range from limited to extensive.  Reliance on quality evidence over clinical evidence may be 
an unusual concept for those that know a biosimilar medicine is ‘similar but not identical’ to the 
reference medicine.  The biosimilar medicine may also be licensed in therapeutic indications for which 
no specific clinical trials have been conducted.  This is commonly referred to as indication 
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extrapolation and is only approved by regulators after comprehensive scientific justification which 
includes consideration of the mechanism of action in each indication.   
 
A key output from the RSI biosimilar project is to identify and implement mechanisms to increase the 
understanding of how these medicines are regulated and used amongst healthcare professionals, 
patients and healthcare providers. 
 
HPRA Guide to Biosimilar Medicines 
 
Prior to commencement of the RSI biosimilar project, the HPRA was already engaged in activities to 
facilitate knowledge transfer concerning biosimilar medicines to stakeholders.  In 2015 the HPRA 
published a guide to biosimilar medicines (3).  This guide is targeted primarily at healthcare 
professionals but is also relevant to patients, manufacturers, distributors and those involved in 
hospital procurement.  Some of the drivers for producing the guide are outlined in Table 1. 
 
Table 1 
Reasons for producing HPRA Guide on Biosimilar Medicines 
• Perceived uncertainty among healthcare professionals  
• Lack of understanding of the biosimilar approval process 
• Misconceptions around indication extrapolation 
• Perceived lack of awareness amongst healthcare professionals (and patients) of the 
differences between a biosimilar and a generic 
• Possible dependence among healthcare professionals on anecdotal information about 
biosimilars 
 
The guide provides an overview of how biosimilar medicines are regulated and outlines the difference 
between a biosimilar medicine and a generic (chemical) medicine.  Topics such as pharmacovigilance 
considerations, adverse drug reaction reporting, prescribing and interchangeability are also 
addressed.  A public consultation process was undertaken before finalisation of the guide which 
allowed the HPRA to gather feedback from stakeholders as to whether it provided enough relevant 
information to meet their needs.  Comments from stakeholders were considered and incorporated as 
appropriate.  While the publication of such guidance documents can help in addressing some of the 
misconceptions surrounding biosimilar medicines, the HPRA is continuing in its efforts to bridge the 
information gap on biosimilar medicines by providing dedicated resources to the RSI Biosimilar 
Research Project.   
 
RSI Biosimilar Research Project  
 
Biosimilar medicines were highlighted as being a key area of interest for the development of the 
regulatory science knowledge base in Ireland and therefore a biosimilar research project was launched 
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as one of the first major projects for RSI.  The project, which has been ongoing since January 2016, 
involves a collaboration between the HPRA and University College Cork (UCC).  The research is also 
supported by the Irish Pharmaceutical Healthcare Association (IPHA).  A project advisory panel meet 
quarterly to share ideas about the direction of the research.  In addition to HPRA and UCC, the advisory 
panel consists of stakeholders from industry, industry representative bodies, a patient representative 
and government agencies.    
 
The project focuses on a number of specific objectives relating to enhanced pharmacovigilance and 
traceability of biological medicines and the need for procurement/purchasing procedures to 
appreciate the difference between biosimilar medicines and generic medicines.   
 
The project objectives include 
• Peer reviewed scientific publications on biosimilar medicines – particularly concerning the 
practical considerations for health care professionals 
• Conducting surveys of healthcare professionals on perspectives and understandings of issues 
relating to biosimilar medicines 
• Development of training materials and online resources 
• Participation in outreach activities (e.g. running short training courses, information days, 
invited lectures) 
 
Research activities are conducted independently by the HPRA and UCC which ensures the generation 
of unbiased neutral information relating to the use of biosimilar medicines by healthcare 
professionals.    
 
Survey of Physicians 
 
An early goal of the project is to evaluate the level of understanding about biosimilar medicines 
amongst Irish healthcare professionals.  In May 2016 a link to an online questionnaire was circulated 
to medical specialists (predominantly hospital consultants in specialities that use biological medicines) 
and general practitioners (GPs).  The objective of this survey was to explore physician’s perspectives 
and understanding of issues relating to biological and biosimilar medicines.  The questionnaire 
addressed topics such as familiarity with the term ‘biosimilar’, implications of shared international 
non-proprietary names, pharmacovigilance recording practices, prescribing behaviours, attitudes to 
pharmacist led substitution and specific concerns relating to biosimilar medicines.  The results from 
the survey are currently being analysed and will shortly be submitted for publication.  
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Stakeholder Engagement 
 
Many medical specialists in Ireland are members of professional societies.  Societies, whose members 
are likely to be involved in the prescribing of biological medicines, have facilitated the research by 
distribution of the online questionnaire to their members.  Continued engagement with the societies 
is envisaged after publication of the survey findings.   
 
Engagement with GPs has been facilitated by The Irish College of General Practitioners (ICGP).  The 
ICGP is the professional body for General Practice in Ireland and its members and associates account 
for over 85% of practising GPs.  The College agreed to distribute the questionnaire to its membership 
and organised a speaking slot for RSI at an educational conference organised for their members.   
 
Pharmacists have been kept informed of key aspects of biosimilar regulation and their use in clinical 
practice via RSI presentations at continuing education events and publication of papers in national 
pharmacy journals (Irish Pharmacy News and the Hospital Pharmacist News).  An article highlighting 
the importance of traceability of biological medicines has been published on the RSI website (4) and 
highlighted to registered pharmacists via a newsletter distributed by the Pharmaceutical Society of 
Ireland. 
 
The RSI project team also aims to facilitate knowledge transfer to patient communities.  
Representatives from various patient organisations have been made aware of the project at a recent 
event on ‘Biologics and Biosimilars’ organised by the Irish Platform for Patient Organisations Science 
and Industry (IPPOSI).  IPPOSI has also conducted a recent survey of 150 arthritis patients (5) .  The 
findings suggest that awareness and understanding of biosimilars amongst patients is low.  
Respondents also felt that there was limited access to patient friendly, easily understandable 
information about biological and biosimilar medicines.  This identified need has resulted in the RSI 
publication of a patient Q&A which can be found on the RSI website (6).  It is planned to produce a 
short informative video to accompany the Q&A.  Once finalised the materials will be publicised to 
relevant patient organisations.    
 
Ongoing Activities 
 
Materials generated from the project will be available for download from the RSI website 
(www.regulatoryscienceireland.ie).  Research findings will be disseminated to healthcare 
professionals, patients, payers and policy makers.  Outreach activities will continue as the project gains 
momentum and it is planned to organise and contribute to future events involving key stakeholders. 
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Conclusion 
 
Since its inception, RSI has made significant progress in increasing the awareness and understanding 
of the regulation, prescription and use of biosimilar medicines in Ireland.  However, a level of 
misunderstanding around the whole area still persists.  Through our future research, outreach 
programmes and engagement activities, RSI plans to bridge the knowledge gap between industry, 
regulators, healthcare professionals and patients and contribute to the safe and effective use of 
biological medicines in Ireland.   
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